Health Canada's Therapeutics Products Directorate has approved BCYLifeSciences' Investigational New Drug application for DCF 987 in the treatment of respiratory diseases such as cystic fibrosis and chronic obstructive pulmonary disease. The company now plans to initiate a Phase I clinical trial in early September, and says that results should be available before the end of 2001.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze